Pharmacokinetic and bioequivalence study of itopride HCl in healthy volunteers

Abstract

In the present study two different formulations containing 50 mg itopride HCl (N-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide HCl, CAS 122898-67-3) were compared in 28 healthy male volunteers in order to compare the bioavailability and prove the bioequivalence. The study was performed in an open, single dose randomized, 2-sequence, crossover design in 28 healthy male volunteers with a one-week washout period. Blood samples for pharmacokinetic profiling were drawn at selected times during 24 h. The serum concentrations of itopride HCl were determined using a specific and sensitive HPLC method with fluorescence detection. The detection limit of itopride HCl was 5 ng/ml and no endogenous compounds were found to interfere with analysis. The mean AUC_0–24h, AUC_0–fi1, C_max, T_max and T_1/2 were 865.28 ng · h/ml, 873.04 ng · h/ml, 303.72 ng/ml, 0.75 h, and 2.95 h, respectively, for the test formulations, and 833.00 ng · h/ml, 830.97 ng · h/ml, 268.01 ng/ml, 0.78 h, and 2.83 h, respectively, for the reference formulation. Both primary target parameters AUC0fi1 and Cmax were log-transformed and tested parametrically by analysis of variance (ANOVA). 90% onfidence intervals of AUC0fi1 and Cmax ere 100.57%–109.56% and 105.46%–21.18%, respectively, and were in the ange of acceptable limits of bioequivalence 80–125%). Based on these results, he two formulations of itopride HCl are onsidered to be bioequivalent.

Key words

CAS 122898-67-3 - Gastro-prokinetic agent - Itopride HCl, bioequivalence study, pharmacokinetics

• References

• 1 Fumihiko K, Toru S, Shin I, Yuhki S, Hiroki I, Masaharu T. Effects of itopride hydrochloride on plasma gut-regulatory peptide and stress-related hormone levels in healthy human subjects. Pharmacology. 2006; 77 (3) 115-21
• 2 Yong Sung K, Tae Hyeon K, Chang Soo C, Young Woo S, Sang Wook K, Geom Seog S et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenter. 2005; 11 (27) 4210-4
• 3 Sono Sundd S, Manish J, Kuldeep S, Bhavin S, Meghna V, Purav T et al. Quantitation of itopride in human serum by high-performance liquid chromatography with fluorescence detection and its application to a bioequivalence study. J Chromatogr B. 2005; 818: 213-20
• 4 Jing M, Li-Hua Y, Mei-Juan D, Jun Z, Qing Z, Qun-Wei X et al. Determination of itopride hydrochloride in human plasma by RP-HPLC with fluorescence detection and its use in bioequivalence study. Pharmacol Res. 2009; 59: 189-93
• 5 Heon-Woo L, Ji-Hyung S, Seung-Ki C, Kyung-Tae L. Determination of itopride in human plasma by liquid chromatography coupled to tandem mass spectrometric detection: application to a bioequivalence study. Anal Chim Acta. 2007; 583: 118-23
• 6 The guideline for bioavailability and bioequivalence: Act No. 86 KFDA; 1998
• 7 Guidance for Industry: Bioanalytical method validation, USDHHS, FDA, CDER, CVM 2001